DNLI
NASDAQ
$22.90
Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $34.25 (+49.56%)
Market Cap
$3.65B
Free Cash Flow Yield
-11.55%
Beta (5Y)
1.45
Price Chart
Valuation
Market Cap$3.65B
P/S3643.65
P/B3.94
Profitability
Gross Profit (TTM)-$406M
EBITDA-$535M
EPS-$3.35
Financial Health
Free Cash Flow Yield-11.55%
Growth & Risk
Beta (5Y)1.45
Sharpe Ratio1.01